

Abstract of Disclosure

The patent application discloses a method and product for the prevention or reversal of weight gain associated with the use of olanzapine or other antipsychotic drugs or with mood stabilizing drugs such as divalproex sodium, valproic acid, mirtazapine or similar anti-mania or antidepressant agents through the concomitant use of histamine H<sub>2</sub>-receptor antagonists such as nizatidine, famotidine, cimetidine and ranitidine. The combination of the psychotropic active drug and the histamine H<sub>2</sub>-receptor antagonist may represent a combined single dose delivery system or a multiple drug regimen taken at the same or different time intervals. A pharmaceutical composition containing the combination psychotropic active agent and a histamine H<sub>2</sub>-receptor antagonist is also disclosed herein.